|
1
|
Bouattour Y, Neflot-Bissuel F, Traïkia M, Biesse-Martin AS, Frederic R, Yessaad M, Jouannet M, Wasiak M, Chennell P, Sautou V. Cyclodextrins Allow the Combination of Incompatible Vancomycin and Ceftazidime into an Ophthalmic Formulation for the Treatment of Bacterial Keratitis. Int J Mol Sci 2021; 22:ijms221910538. [PMID: 34638878 PMCID: PMC8508691 DOI: 10.3390/ijms221910538] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 09/24/2021] [Accepted: 09/27/2021] [Indexed: 01/31/2023] Open
Abstract
Ceftazidime (CZ) and vancomycin (VA) are two antibiotics used to treat bacterial keratitis. Due to their physical incompatibility (formation of a precipitate), it is not currently possible to associate both molecules in a single container for ophthalmic administration. We firstly characterized the incompatibility then investigated if 2-hydroxypropyl-beta (HPβCD) and 2-hydroxypropyl-gamma cyclodextrins (HPγCD) could prevent this incompatibility. The impact of pH on the precipitation phenomena was investigated by analysing the supernatant solution of the mixture using high performance liquid chromatography. A characterization of the inclusion of CZ with HPγCD using 1H nuclear magnetic resonance (NMR), and VA with HPβCD using 1H-NMR and a solubility diagram was performed. A design of experiment was built to determine the optimal conditions to obtain a formulation that had the lowest turbidity and particle count. Our results showed that VA and CZ form an equimolar precipitate below pH 7.3. The best formulation obtained underwent an in-vitro evaluation of its antibacterial activity. The impact of HPCDs on incompatibility has been demonstrated through the inclusion of antibiotics and especially VA. The formulation has been shown to be able to inhibit the incompatibility for pH higher than 7.3 and to possess unaltered antibacterial activity.
Collapse
Affiliation(s)
- Yassine Bouattour
- Université Clermont Auvergne, CHU Clermont Ferrand, Clermont Auvergne INP, CNRS, ICCF, F-63000 Clermont-Ferrand, France; (Y.B.); (V.S.)
| | - Florent Neflot-Bissuel
- CHU Clermont-Ferrand, Pôle Pharmacie, F-63000 Clermont-Ferrand, France; (F.N.-B.); (M.Y.); (M.J.); (M.W.)
| | - Mounir Traïkia
- Université Clermont Auvergne, CNRS, SIGMA-Clermont, ICCF, F-63000 Clermont-Ferrand, France; (M.T.); (A.-S.B.-M.)
| | - Anne-Sophie Biesse-Martin
- Université Clermont Auvergne, CNRS, SIGMA-Clermont, ICCF, F-63000 Clermont-Ferrand, France; (M.T.); (A.-S.B.-M.)
| | - Robin Frederic
- Université Clermont Auvergne, Inserm U1071, INRA USC2018, F-63000 Clermont-Ferrand, France;
| | - Mouloud Yessaad
- CHU Clermont-Ferrand, Pôle Pharmacie, F-63000 Clermont-Ferrand, France; (F.N.-B.); (M.Y.); (M.J.); (M.W.)
| | - Mireille Jouannet
- CHU Clermont-Ferrand, Pôle Pharmacie, F-63000 Clermont-Ferrand, France; (F.N.-B.); (M.Y.); (M.J.); (M.W.)
| | - Mathieu Wasiak
- CHU Clermont-Ferrand, Pôle Pharmacie, F-63000 Clermont-Ferrand, France; (F.N.-B.); (M.Y.); (M.J.); (M.W.)
| | - Philip Chennell
- Université Clermont Auvergne, CHU Clermont Ferrand, Clermont Auvergne INP, CNRS, ICCF, F-63000 Clermont-Ferrand, France; (Y.B.); (V.S.)
- Correspondence:
| | - Valerie Sautou
- Université Clermont Auvergne, CHU Clermont Ferrand, Clermont Auvergne INP, CNRS, ICCF, F-63000 Clermont-Ferrand, France; (Y.B.); (V.S.)
| |
Collapse
|